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Abstract
Treatment of non-small cell lung cancer (NSCLC) is challenging in many ways. One of the problems is
disappointing local control rates in larger volume disease. Moreover, the likelihood of both nodal and distant
spread increases with primary tumour (T-) stage. Many patients are elderly and have considerable comorbidity.
Therefore, aggressive combined modality treatment might be contraindicated or poorly tolerated. In many cases
with larger tumour volume, sufficiently high radiation doses can not be administered because the tolerance of
surrounding normal tissues must be respected. Under such circumstances, simultaneous administration of
radiosensitizing agents, which increase tumour cell kill, might improve the therapeutic ratio. If such agents have a
favourable toxicity profile, even elderly patients might tolerate concomitant treatment. Based on sound preclinical
evidence, several relatively small studies have examined radiotherapy (RT) with cetuximab in stage III NSCLC. Three
different strategies were pursued: 1) RT plus cetuximab (2 studies), 2) induction chemotherapy followed by RT plus
cetuximab (2 studies) and 3) concomitant RT and chemotherapy plus cetuximab (2 studies). Radiation doses were
limited to 60-70 Gy. As a result of study design, in particular lack of randomised comparison between cetuximab
and no cetuximab, the efficacy results are difficult to interpret. However, strategy 1) and 3) appear more promising
than induction chemotherapy followed by RT and cetuximab. Toxicity and adverse events were more common
when concomitant chemotherapy was given. Nevertheless, combined treatment appears feasible. The role of
consolidation cetuximab after RT is uncertain. A large randomised phase III study of combined RT, chemotherapy
and cetuximab has been initiated.
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Introduction
Non-small cell lung cancer (NSCLC) is among the lead-
ing causes of cancer death in the western world and
increasing in many other countries. Survival of patients
with locoregionally advanced disease (stage III) and
metastatic disease has remained disappointing despite
some gradual improvement [1,2]. Patients with stage III
disease differ with regard to primary tumour volume
and proximity/infiltration to surrounding structures,
extent of lymphatic spread, cancer biology, and host fac-
tors such as age, cardiopulmonary function and other
comorbidity [3]. Treatment recommendations have to
take into account these differences and stratify patients
according to technical resectability, ability to tolerate
high-dose radiotherapy and chemotherapy, and many
more.
Many patients with inoperable stage III disease are
candidates for combined modality chemo- and radio-
therapy (RT). While concomitant administration might
improve survival, parallel increases of toxicity have also
been observed [1,4]. The dilemma of simultaneous
increases in efficacy and toxicity becomes even more
difficult in elderly patients and those with considerable
pretreatment weight loss, reduced performance status
and comorbidity. Incorporation of novel agents might
be advantageous in several ways. It might allow for
administration of combined modality treatment in
patients who are not candidates for established chemor-
adiation regimens and where RT alone results in unsa-
tisfactory outcomes. Moreover, certain agents might be
added on top of chemoradiation with the aim of further * Correspondence: carsten.nieder@nlsh.no
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aggressive approaches.
The theoretical solution of simply increasing radiation
doses to high biologically effective doses (BED), ideally
above the threshold of 100 Gy in 2-Gy fractions, which
has been suggested by several groups [5-8], is hampered
by the tolerance of surrounding normal tissues that
must be respected if a favourable therapeutic ratio is to
be maintained. Under such circumstances, simultaneous
administration of radiosensitizing agents that increase
tumour cell kill might improve the therapeutic ratio,
provided these agents do not sensitize critical normal
tissues in the same fashion. Moreover, radiation dose
escalation does not address the issue of distant or out-
of-field relapses. Based on the fact that the epidermal
growth factor receptor (EGFR) is often over-expressed
or mutated in NSCLC, the impact of such changes on
cellular responses to ionising radiation has been
explored [9-11]. Several drugs interfering with the EGFR
signalling pathway have been developed, e.g. cetuximab,
a human-murine chimeric IgG1 monoclonal antibody
that binds to the extracellular region of the EGFR.
Under experimental laboratory conditions in animal
models, cetuximab increases tumour radiocurability
(fractionated and single dose irradiation) [12,13]. Clini-
cally, this effect has been confirmed in head and neck
cancer (phase III data with fractionated irradiation) [14].
Recently, initial clinical trials of cetuximab and RT for
NSCLC have been completed, which are reviewed here
in order to guide the development of the next genera-
tion of larger prospective studies. The data included in
this review were identified by comprehensive searches of
the PubMed database with combinations of the key-
words “NSCLC, RT, cetuximab, EFGR” (last access
August 15, 2011) and the reference lists of articles.
Cetuximab in patients who are not candidates for
chemoradiation
As summarized in Tables 1 and 2, two different phase II
trials have studied combined RT and cetuximab without
any chemotherapy [15,16]. In the US trial, cetuximab
was given concomitant to 60 Gy RT [15]. In the Ger-
man trial, intensity-modulated RT to a total dose of 66
Gy was combined with concomitant and 13 weekly con-
solidation cycles of cetuximab [16]. Another important
difference is that positron emission tomography (PET)
was mandatory in the German trial, which also included
patients with slightly more favourable baseline prognos-
tic factors (some stage II patients, no weight loss > 5%,
younger median age). Median survival and response
rates were higher in the German trial. However, such
differences might result from treatment itself or inclu-
sion of prognostically better patients. Mucosal and pul-
monary toxicities occurred at the expected frequencies
in patients irradiated for stage III NSCLC (elective nodal
irradiation (ENI) was part of the treatment concept) but
overall compliance and tolerability suggest that conco-
mitant cetuximab and standard dose RT (60-66 Gy) is
feasible even in patients unfit for chemoradiation. The
median survival of 15.1 and 19.6 months respectively
compares favourably with trials of comparable RT alone,
e.g. the series of 127 patients reported by Jeremic et al.
who found a median survival of 12 months [17], and the
series of 106 patients reported by Wang et al. where
median survival was 7.4 months [18]. However, such
inter-study comparison might be hampered by several
sources of bias (patient selection, improved staging,
improved RT delivery etc.) and can not prove the super-
iority of combined treatment. Randomised comparison
of RT alone and RT with cetuximab is still necessary. It
would also be interesting to study whether irradiation to
60-66 Gy plus cetuximab is better than dose-escalated
RT without cetuximab, given the high cost resulting
from drug treatment.
Cetuximab and chemoradiation: induction chemotherapy
only
Two phase II studies have been published, as shown in
Tables 1 and 2[19,20]. Both included patients with inop-
erable stage III disease and good performance status. In
the Swedish study, 2 cycles of induction cisplatin/doce-
taxel were administered [19]. The small UK study with a
median of 3 cycles included patients treated with differ-
ent regimens [20]. In both studies cetuximab was given
concomitant to RT (total dose 64 and 68 Gy, respec-
tively). ENI was administered to selected patients in the
UK trial only. Serial computed tomography (CT)
revealed that the UK trial included some patients with
actual stage IV disease. Only the Swedish trial reported
detailed outcome data. Median survival was 17 months,
i.e. comparable to the results of the two trials without
any chemotherapy [15,16] or other studies of sequential
chemotherapy and RT without cetuximab [18]. Toxicity
a n dc o m p l i a n c ew e r ea l s oc o m p a r a b l et ot h e s ea f o r e -
mentioned studies. In the absence of randomised trials,
these sparse data do not create enthusiasm about
further studies of comparable approaches. It appears
more attractive to put resources into trials of the other
two categories reviewed here.
Cetuximab and chemoradiation: concomitant
chemotherapy
The Radiation Therapy Oncology Group (RTOG) has
recently published a phase II study of chemoradiother-
apy with carboplatin and paclitaxel plus cetuximab in
patients with stage III NSCLC [21]. From the loading
dose of cetuximab to the end of the consolidation
phase, 17 weekly treatments were administered. The
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motherapy was administered concurrently and in the
consolidation phase. The authors concluded that treat-
ment was feasible and survival longer than any pre-
viously reported by the RTOG. Median survival was
22.7 months. However, median time to progression was
approximately 14-15 months (estimated from the
graph). In other words, early cancer progression con-
tinues to be common. Moreover, RTOG trial 0117
reported median survival of 21.6 months in 44 patients
with inoperable stage III NSCLC treated with 74 Gy and
concomitant carboplatin/paclitaxel [22]. Median survival
was numerically longer in the cetuximab trial but the
absolute difference was 1 month. The second trial in
this category was also completed in the US [23]. Several
important differences exist (mandatory PET, higher
radiation dose of 70 Gy, only 7 weeks of cetuximab con-
comitant to RT, chemotherapy with carboplatin and
pemetrexed). Median survival was 25.2 months and fail-
ure-free survival 12.3 months. Given the large
Table 1 Study design and efficacy
Reference Study type Patients Other criteria RT schedule Systemic therapy Follow-
up
Results
Jensen et al.
[16]
Single
institution
phase II,
Germany, n
=3 0
Not candidates for
concomitant
chemoradiation
(or refused), KPS at
least 70, one of
two trials with
mandatory PET
Stage IIIA or B,
no malignant
pleural effusion,
FEV1 ≥ 1.5 l or
40% of norm
value, weight
loss < 5%
Only IMRT trial, 66
Gy in 33 daily
fractions of 2 Gy,
ENI to 50 Gy (or
40 depending on
lung dose, target
volume NR)
Cetuximab SR
followed by 13 weekly
consolidation cycles
Median
19 mo
Median OS 19.6 mo,
median PFS 8.5 mo,
63% PR, no CR,
patterns of failure NR,
survival not influenced
by histology
Jatoi et al. [15] Multi-centre
phase II, US,
n=5 8
Not candidates for
concomitant
chemoradiation,
either age ≥ 65
years with ECOG
0-2 or younger
but ECOG 2
Stage III A or B,
no pleural
effusion, FEV1 ≥
1l ,
haemoglobin ≥
9 g/dl, V20 not
exceeding 40%
60 Gy in 30 daily
fractions of 2 Gy,
ENI to ipsilateral
hilar and
mediastinal nodes
(44 Gy)
Cetuximab SR Median
17 mo
Median OS 15.1 mo,
median PFS 7.2 mo,
26% PR, no CR,
patterns of failure and
impact of histology NR
Hallqvist et al.
[19]
Multi-centre
phase II,
Sweden, n =
71
Medically
inoperable or
unresectable,
WHO 0-1
Stage IIIA or B,
no pleural
effusion with
positive
cytology, FEV1
≥ 1 l or 40% of
expected
volume
68 Gy in 34 daily
fractions of 2 Gy,
no ENI
2 cycles of induction
cisplatin/docetaxel,
cetuximab SR starting
one week before RT
Median
39 mo
Median OS 17 mo, PFS
NR, 16% PR and 7% CR
at 12 months (NR at
earlier time points),
patterns of failure: 31%
distant only, 23% local
only, 7% regional only,
11% combinations of
these, survival not
influenced by histology
Hughes et al.
[20]
Dual centre
phase II, UK,
n=1 2
Inoperable, WHO
0-1
Stage IIIA or B,
no pleural
effusion
64 Gy in 32
fractions of 2 Gy,
in 4 cases ENI to
ipsilateral hilar and
mediastinal nodes
(50 Gy)
Up to 4 cycles
(median 3) of
platinum-based
induction CTx,
cetuximab SR starting
one week before RT
Median
10 mo
Median OS NR, PFS NR,
58% PR, no CR,
patterns of failure and
impact of histology NR
Blumenschein
et al. [21]
Multi-centre
phase II, US,
n=8 7
Inoperable,
Zubrod 0-1
Stage IIIA or B,
weight loss <
5%, FEV1 ≥ 1,2 l
63 Gy in 35
fractions of 1.8 Gy,
ENI to ipsilateral
hilar and
mediastinal nodes
(45 Gy)
Cetuximab SR week 1-
17, weekly
carboplatin/paclitaxel
during RT followed by
2 cycles consolidation
carboplatin/paclitaxel
Median
22 mo
Median OS 22.7 mo,
median time to
progression around 14-
15 mo, 29% CR, 33%
PR, patterns of failure
and impact of
histology NR
Govindan et
al. [23]
Multi-centre
phase II,
randomised,
US, n = 101
Inoperable, ECOG
0-1, one of two
trials with
mandatory PET
Stage IIIA or B,
no pleural
effusion, weight
loss ≤ 10%
70 Gy in 35
fractions of 2 Gy,
no ENI
Cetuximab SR (7
weeks) plus 4 cycles
carboplatin/
pemetrexed vs. same
CTx without
cetuximab (n = 48),
afterwards 4 cycles of
pemetrexed
Median
32 mo
Median OS 25.2 mo*,
median failure-free
survival 12.3 mo, 4%
CR, 68% PR, patterns of
failure NR, survival not
influenced by histology
RT: radiotherapy; IMRT: intensity-modulated radiotherapy; CTx: chemotherapy; KPS: Karnofsky performance status; ECOG: Eastern Cooperative Oncology Group
performance status; WHO: World Health Organisation performance status; FEV1: forced expiratory volume 1; V20: lung volume receiving 20 Gy; ENI: elective nodal
irradiation; Cetuximab SR: standard regimen with 400 mg/m
2 given i.v. on day 1 and 250 mg/m
2 on days 8, 15, 22, 29, 36 and 43; OS: overall survival; PFS:
progression-free survival; PR and CR: partial and complete remission as per RECIST criteria; NR: not reported; PET: positron emission tomography
* all results relate to the cetuximab arm of the study
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appears difficult. It is important to mention that the two
trials reviewed in this category reported higher rates of
treatment-related deaths and adverse events than all the
other studies where no concomitant chemotherapy was
given. However, they also reported encouraging survival
results, which led the investigators to initiate a confir-
matory intergroup phase III trial that will clarify the role
of additional cetuximab in this setting (RTOG 0617).
Compared to other phase II studies without cetuximab,
the survival results found in the two US trials are good
but not exceptional. Table 3 contains a brief summary
of relevant data, including selected arms from rando-
mised trials, illustrating the possibility of impressive sur-
vival outcomes with quite different approaches. As
mentioned previously, several sources of bias make com-
parisons between all these studies unreliable. Therefore,
the present overview can not provide definitive
recommendations.
Discussion
Historically, the added value of cetuximab has been pro-
ven in a pivotal head and neck cancer radiotherapy trial,
which did not include cytotoxic chemotherapy [14].
This trial confirmed preclinical results obtained in dif-
ferent in vitro and in vivo models [9-13]. The NSCLC
studies reviewed in the present article suggest that con-
ventional fractionated RT (3-D conformal or intensity-
modulated) to a maximum dose of 70 Gy can safely be
combined with cetuximab. With additional concomitant
chemotherapy, toxicity increases to the high degree that
has been observed in several studies of simultaneous
chemoradiation without cetuximab [1,4,6]. Over 60% of
patients developed ≥ grade 3 non-hematologic adverse
events and comparable figures were reported for ≥
grade 3 hematologic adverse events, which contributed
to the fact that approximately 20% of patients were
unable to complete treatment [21,23]. Importantly, no
randomised head-to-head comparison of any of the 3
strategies reviewed here (RT plus cetuximab, induction
chemotherapy followed by RT plus cetuximab, concomi-
tant chemoradiation plus cetuximab) has yet been pub-
lished. Therefore, both toxicity and efficacy results must
be interpreted with caution. Non-randomised head and
neck cancer studies suggested promising efficacy of
combined cetuximab, RT and chemotherapy [24-26].
However, the phase III trial RTOG 0522 could not con-
firm improved progression-free or overall survival when
Table 2 Baseline characteristics and adverse events (AE)
Reference Median
age
Performance
status
Stage Weight
loss
Histology Adverse events (AE)
Jensen et al.
[16]
71 years
(57-82)
NR II: 7%
IIIA:
57%
IIIB:
37%
Weight loss
<5 %
required
Adenocarcinoma:
33%
Squamous: 57%
Other or
unknown: 10%
10% died before completing protocol treatment (death unlikely
related to treatment), 50% had ≥ grade 3 non-hematologic AE
Jatoi et al. [15] 77 years
(60-87)
0: 22%
1: 57%
2: 21%
IIIA:
59%
IIIB:
41%
NR Adenocarcinoma:
38%
Squamous: 43%
Other or
unspecified: 19%
No treatment-related deaths, 9% stopped early because of AE,
53% had at least one AE ≥ grade 3
Hallqvist et al.
[19]
62 years
(42-81)
0: 62%
1: 38%
IIIA:
37%
IIIB:
63%
> 5%: 37% Adenocarcinoma:
49%
Squamous: 39%
Unspecified: 12%
One pneumonitis-related death, 18% did not complete
cetuximab and 11% received < 68 Gy, 43% AE ≥ grade 3
Hughes et al.
[20]
67.5
years
(58-76)
0: 42%
1: 58%
IIIA:
33%
IIIB:
50%
IV:
17%
NR Adenocarcinoma:
33%
Squamous: 50%
Other or
unspecified: 17%
One pneumonia-related death, 17% did not complete
cetuximab, 17% AE ≥ grade 3
Blumenschein
et al. [21]
64 years
(42-85)
0: 47%
1: 53%
IIIA:
46%
IIIB:
54%
Weight loss
<5 %
required
NR 6 treatment-related deaths, 20% did not complete RT and
concurrent cetuximab, 68% had ≥ grade 3 non-hematologic AE
Govindan et
al. [23]*
66 years
(32-81)
0: 34%
1: 66%
IIIA:
53%
IIIB:
47%
Weight loss
≤ 10%
required
Adenocarcinoma:
42%
Squamous: 34%
Other or
unspecified: 25%
3 treatment-related deaths, 19% did not complete 4 cycles of
CTx and 7 weeks of cetuximab, 62% had ≥ grade 3 non-
hematologic AE and 70% ≥ grade 3 hematologic AE
NR: not reported; RT: radiotherapy
*data shown are for patients in the cetuximab arm of this randomised study
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ing results have also been reported for rectal cancer
[28].
This review does not attempt to provide treatment
recommendations. Its purpose is to contribute to the
development of future, large-scale prospective studies.
Such studies seem warranted mainly in two settings 1)
RT plus cetuximab in patients who can not tolerate che-
moradiation, and 2) concomitant chemoradiation plus
cetuximab in patients who qualify for such aggressive
regimens. Regarding the latter approach, a randomised
intergroup study based on the results of the RTOG trial
[21] is under way. A question that will not be answered
in this trial is the optimal duration of cetuximab treat-
ment, provided there is a definitive benefit from this
drug. As reviewed here, some groups chose to limit
drug administration to the concomitant phase with RT
while others continued cetuximab for longer durations.
Given the cost of such treatment, the added value of
extended cetuximab therapy must be proven in appro-
priate randomised settings. Other well recognised areas
of controversy that apply to all NSCLC RT strategies
including the cetuximab trials, are the role of ENI
[7,8,29], PET for staging and treatment planning
[8,30-32], radiation dose escalation [8,18,22] and conso-
lidation chemotherapy after chemoradiation [2,33]. The
variations in the 6 studies reviewed here nicely illustrate
the uncertainties around these issues. None of these stu-
dies used accelerated RT regimens or hypofractionation
in combination with cetuximab. However, altered frac-
tionation RT resulting in shorter overall treatment time
is one of the possibilities to improve NSCLC outcomes
[34,35].
Histology has gained increasing importance for the
choice of NSCLC systemic therapy but had no signifi-
cant influence on survival in the 3 cetuximab plus RT
studies that looked at this parameter [16,19,23].
Whether these studies truly suggest that inclusion of
any histologic type of NSCLC into future trials should
be considered remains an open question, given their
limited sample size and statistical power. However, indi-
vidually tailored treatment has the potential to improve
cost-effectiveness and spare patients from unnecessary
toxicity. Unfortunately, at present no established bio-
marker or histology feature has gained widespread
acceptance. A recent analysis of a phase III study
(BMS099; taxane/carboplatin with or without cetuximab;
no radiotherapy) where tumour samples from 225
patients were examined, did not find significant associa-
tions between KRAS and EGFR and various outcome
parameters [36]. Also in the phase III FLEX study (cis-
platin/vinorelbine with or without cetuximab; no radio-
therapy) biomarkers (KRAS, EGFR, PTEN) did not
predict treatment efficacy [37]. On the basis of all avail-
able data, it is not justified to exclude molecular sub-
groups of NSCLC from future RT and cetuximab
studies. However, it is important to conduct additional
biomarker analyses in these future studies. If EGFR inhi-
bition increases the clinical efficacy of RT for stage III
NSCLC, cetuximab might not be the only agent exerting
this effect. Preliminary experience with tyrosine kinase
inhibitors and thoracic RT has been published [38,39].
However, these small non-randomised studies suffer
f r o mt h es a m el i m i t a t i o n sa st h o s er e v i e w e dh e r ea n d
have not provided definitive data. Because the presence
of EGFR mutations in general is predictive of respon-
siveness to EGFR tyrosine kinase inhibitors, adenocarci-
noma or NSCLC not otherwise specified should be
tested for such alterations [40].
Conclusions
The results of the 6 published clinical trials (none of
them was a phase III study) suggest that larger rando-
mised trials are warranted, primarily addressing the role
Table 3 Results of other recent chemoradiation trials, unresectable stage III (without cetuximab)
Author, patient
number
Treatment Median survival
(PFS)
Bepler et al. [41], 39 2 cycles induction carboplatin and gemcitabine, RT up to 74 Gy (mean 70) with weekly carboplatin
and paclitaxel
22.7 mo
(14.3 mo)
Socinski et al. [42], 43 2 cycles induction carboplatin and paclitaxel, RT 74 Gy with weekly carboplatin and paclitaxel 24.3 mo
Krzakowski et al. [43],
54
2 cycles induction cisplatin and vinorelbine, RT 66 Gy with 2 cycles cisplatin and vinorelbine 23.4 mo
(12.5 mo)
Sejpal et al. [44], 62 Weekly carboplatin and paclitaxel, RT median 74 Gy with protons 24.4 mo
Segawa et al. [45], 99 RT 60 Gy with 4 cycles of concomitant cisplatin and docetaxel 26.8 mo
(13.4 mo)
Cho et al. [46], 49 Weekly carboplatin and paclitaxel, RT 60 Gy in 25 fractions 28.1 mo
(13.7 mo)
Gandara et al. [47], 83 RT 61 Gy with 2 cycles of concomitant cisplatin and etoposide, consolidation docetaxel 26 mo
(16 mo)
RT: radiotherapy; PFS: progression-free survival
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moradiation and combined chemoradiation plus cetuxi-
mab in prognostically better patients. Correlative
biomarker studies should be part of these research
efforts.
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